| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* The Wistar Institute, and
University of Pennsylvania, Philadelphia, PA 19104;
Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702;
Centro de Investigacion en Ciencia Aplicada y Tecnologia Avanzada del Instituto Politecnico Nacional, Mexico City, Mexico
In animal models, E1-deleted human adenoviral recombinants of the serotype 5 (AdHu5) have shown high efficacy as vaccine carriers for different Ags including those of HIV-1. Humans are infected by common serotypes of human adenovirus such as AdHu5 early in life and a significant percentage has high levels of neutralizing Abs to these serotypes, which will very likely impair the efficacy of recombinant vaccines based on the homologous virus. To circumvent this problem, a novel replication-defective adenoviral vaccine carrier based on an E1-deleted recombinant of the chimpanzee adenovirus 68 (AdC68) was developed. An AdC68 construct expressing a codon-optimized, truncated form of gag of HIV-1 induces CD8+ T cells to gag in mice which at the height of the immune response encompass nearly 20% of the entire splenic CD8+ T cell population. The vaccine-induced immune response provides protection to challenge with a vaccinia gag recombinant virus. Induction of transgene-specific CD8+ T cells and protection against viral challenge elicited by the AdC68 vaccines is not strongly inhibited in animals preimmune to AdHu5 virus. However, the response elicited by the AdHu5 vaccine is greatly attenuated in AdHu5 preimmune animals.
This article has been cited by other articles:
|
|
 |
|
  L. H. Haut and H. C. J. Ertl Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine J. Leukoc. Biol., October 1, 2009; 86(4): 779 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Pichla-Gollon, S.-W. Lin, S. E. Hensley, M. O. Lasaro, L. Herkenhoff-Haut, M. Drinker, N. Tatsis, G.-P. Gao, J. M. Wilson, H. C. J. Ertl, et al. Effect of Preexisting Immunity on an Adenovirus Vaccine Vector: In Vitro Neutralization Assays Fail To Predict Inhibition by Antiviral Antibody In Vivo J. Virol., June 1, 2009; 83(11): 5567 - 5573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tatsis, M. O. Lasaro, S.-W. Lin, Z. Q. Xiang, D. Zhou, L. DiMenna, H. Li, A. Bian, S. Abdulla, Y. Li, et al. Adenovirus Vector-Induced Immune Responses in Nonhuman Primates: Responses to Prime Boost Regimens J. Immunol., May 15, 2009; 182(10): 6587 - 6599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, B. A. Ewald, D. M. Lynch, M. Denholtz, P. Abbink, A. A. C. Lemckert, A. Carville, K. G. Mansfield, M. J. Havenga, J. Goudsmit, et al. Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys J. Virol., May 15, 2008; 82(10): 4844 - 4852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Schoenly and D. B. Weiner Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business" J. Virol., April 1, 2008; 82(7): 3166 - 3180. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rodriguez, J. Goudsmit, A. Companjen, R. Mintardjo, G. Gillissen, D. Tax, J. Sijtsma, G. J. Weverling, L. Holterman, D. E. Lanar, et al. Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1 Infect. Immun., April 1, 2008; 76(4): 1709 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tatsis, J. C. Fitzgerald, A. Reyes-Sandoval, K. C. Harris-McCoy, S. E. Hensley, D. Zhou, S.-W. Lin, A. Bian, Z. Q. Xiang, A. Iparraguirre, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines Blood, September 15, 2007; 110(6): 1916 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Santra, Y. Sun, J. G. Parvani, V. Philippon, M. S. Wyand, K. Manson, A. Gomez-Yafal, G. Mazzara, D. Panicali, P. D. Markham, et al. Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors J. Virol., August 15, 2007; 81(16): 8563 - 8570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. McCoy, N. Tatsis, B. Korioth-Schmitz, M. O. Lasaro, S. E. Hensley, S.-W. Lin, Y. Li, W. Giles-Davis, A. Cun, D. Zhou, et al. Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors J. Virol., June 15, 2007; 81(12): 6594 - 6604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Holst, C. Bartholdy, A. Stryhn, A. R. Thomsen, and J. P. Christensen Rapid and sustained CD4+ T-cell-independent immunity from adenovirus-encoded vaccine antigens J. Gen. Virol., June 1, 2007; 88(6): 1708 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Pichla-Gollon, M. Drinker, X. Zhou, F. Xue, J. J. Rux, G.-P. Gao, J. M. Wilson, H. C. J. Ertl, R. M. Burnett, and J. M. Bergelson Structure-Based Identification of a Major Neutralizing Site in an Adenovirus Hexon J. Virol., February 15, 2007; 81(4): 1680 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Thorner, A. A. C. Lemckert, J. Goudsmit, D. M. Lynch, B. A. Ewald, M. Denholtz, M. J. E. Havenga, and D. H. Barouch Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity J. Virol., December 15, 2006; 80(24): 12009 - 12016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Thorner, R. Vogels, J. Kaspers, G. J. Weverling, L. Holterman, A. A. C. Lemckert, A. Dilraj, L. M. McNally, P. M. Jeena, S. Jepsen, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-saharan Africa. J. Clin. Microbiol., October 1, 2006; 44(10): 3781 - 3783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Capone, A. Meola, B. B. Ercole, A. Vitelli, M. Pezzanera, L. Ruggeri, M. E. Davies, R. Tafi, C. Santini, A. Luzzago, et al. A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti-Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques J. Virol., February 15, 2006; 80(4): 1688 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stone, S. Barzee, V. Snarsky, K. Kee, C. A. Spina, X.-F. Yu, and R. S. Kornbluth Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA Vaccines J. Virol., February 15, 2006; 80(4): 1762 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. A. E. Ophorst, K. Radosevic, M. J. E. Havenga, M. G. Pau, L. Holterman, B. Berkhout, J. Goudsmit, and M. Tsuji Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice Infect. Immun., January 1, 2006; 74(1): 313 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Barratt-Boyes, A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors J. Gen. Virol., January 1, 2006; 87(1): 139 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Longhi, B. Sivasankar, N. Omidvar, B. P. Morgan, and A. Gallimore Cutting Edge: Murine CD59a Modulates Antiviral CD4+ T Cell Activity in a Complement-Independent Manner J. Immunol., December 1, 2005; 175(11): 7098 - 7102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nanda, D. M. Lynch, J. Goudsmit, A. A. C. Lemckert, B. A. Ewald, S. M. Sumida, D. M. Truitt, P. Abbink, M. G. Kishko, D. A. Gorgone, et al. Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys J. Virol., November 15, 2005; 79(22): 14161 - 14168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Hensley, W. Giles-Davis, K. C. McCoy, W. Weninger, and H. C. J. Ertl Dendritic Cell Maturation, but Not CD8+ T Cell Induction, Is Dependent on Type I IFN Signaling during Vaccination with Adenovirus Vectors J. Immunol., November 1, 2005; 175(9): 6032 - 6041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hashimoto, J. L. Boyer, N. R. Hackett, J. M. Wilson, and R. G. Crystal Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity Infect. Immun., October 1, 2005; 73(10): 6885 - 6891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. C. Lemckert, S. M. Sumida, L. Holterman, R. Vogels, D. M. Truitt, D. M. Lynch, A. Nanda, B. A. Ewald, D. A. Gorgone, M. A. Lifton, et al. Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity J. Virol., August 1, 2005; 79(15): 9694 - 9701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Sumida, D. M. Truitt, A. A. C. Lemckert, R. Vogels, J. H. H. V. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, et al. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein J. Immunol., June 1, 2005; 174(11): 7179 - 7185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Facciabene, L. Aurisicchio, and N. La Monica Baculovirus Vectors Elicit Antigen-Specific Immune Responses in Mice J. Virol., August 15, 2004; 78(16): 8663 - 8672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Reyes-Sandoval, J. C. Fitzgerald, R. Grant, S. Roy, Z. Q. Xiang, Y. Li, G. P. Gao, J. M. Wilson, and H. C. J. Ertl Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian Serotypes J. Virol., July 15, 2004; 78(14): 7392 - 7399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Barouch, M. G. Pau, J. H. H. V. Custers, W. Koudstaal, S. Kostense, M. J. E. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, et al. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity J. Immunol., May 15, 2004; 172(10): 6290 - 6297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Sumida, D. M. Truitt, M. G. Kishko, J. C. Arthur, S. S. Jackson, D. A. Gorgone, M. A. Lifton, W. Koudstaal, M. G. Pau, S. Kostense, et al. Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors J. Virol., March 15, 2004; 78(6): 2666 - 2673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pinto, J. C. Fitzgerald, W. Giles-Davis, G. P. Gao, J. M. Wilson, and H. C. J. Ertl Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers J. Immunol., December 15, 2003; 171(12): 6774 - 6779. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
